Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer

Purpose To determine the maximum tolerated dose (MTD) of F14512, a topoisomerase II inhibitor designed to target cancer cells through the polyamine transport system, (three-hour daily infusion given for 3 consecutive days every 3 weeks) in platinum-refractory or resistant ovarian cancer. Other objec...

Descripción completa

Detalles Bibliográficos
Autores principales: Leary, Alexandra, Le Tourneau, Christophe, Varga, Andrea, Sablin, Marie-Paule, Gomez-Roca, Carlos, Guilbaud, Nicolas, Petain, Aurelie, Pavlyuk, Mariya, Delord, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647401/
https://www.ncbi.nlm.nih.gov/pubmed/30547316
http://dx.doi.org/10.1007/s10637-018-0688-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647401/
https://www.ncbi.nlm.nih.gov/pubmed/30547316
http://dx.doi.org/10.1007/s10637-018-0688-4

Ejemplares similares